Physician profile
Michael D Smar
NPI 1457349706
$12,342.21
in general payments reported to CMS, 2019-2025
54 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $1,354 · 2021: $2,237 · 2022: $2,197 · 2023: $2,053 · 2024: $1,548 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,116 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,115.63 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,351.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,322.55 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,013.67 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Amarin Pharma, INC. | $926.90 | 2019-2022 | |
| Novo Nordisk INC | $872.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $701.43 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $541.62 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $510.58 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Amgen INC. | $469.85 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $311.42 | 2019-2024 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $308.71 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Currax Pharmaceuticals LLC | $302.19 | 2020-2025 | Contrave, Onzetra Xsail, Nexlizet |
| Exact Sciences Corporation | $283.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $268.02 | 2019-2022 | |
| Lilly USA, LLC | $267.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.